Clinical Trial Update: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors [Phase 2]

View source ↗

Summary

Jazz Pharmaceuticals is conducting a Phase 2 trial of Zanidatamab in HER2-expressing tumors across multiple cancers. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Endometrial Cancer
• Esophageal Cancer
• Gastric Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Pancreatic Cancer

Drugs mentioned

• Zanidatamab

Snippet

Sponsor: Jazz Pharmaceuticals | Conditions: Breast Cancer, Gastric Cancer | Phase 2 | Status: RECRUITING